Press Room

Filter by year:
April 16, 2020

As the Global Crisis Evolves, Publishers are Focusing on Digital with a Renewed Sense of Urgency

By understanding their platform’s capabilities and following best practices, publishers can be confident in their digital strategy during these uncertain times. There’s little doubt that the COVID-19 pandemic has changed the digital publishing landscape. Supply chain disruptions and reduced ad spending are forcing publishers to take a hard look at their short and long-term digital…

Read more
March 5, 2020

Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture.  The lecture will take place May 6th at the Sunnyvale…

Read more
March 5, 2020

Perceptimed Awarded NIH Development Grant

PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT   MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities.  Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as the principal investor and scientific…

Read more
January 8, 2020

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b study of lead programme Icosabutate…

Read more